Adding a long-acting muscarinic antagonist (LAMA) to inhaled corticosteroids (ICS) and long-acting β2-agonists (LABAs) reduces exacerbations in people with moderate to severe persistent asthma, a systematic review and meta-analysis shows. However the use of triple therapy over dual therapy (ICS and LABA) resulted in only small improvements in lung function, and little to no change ...
Add-on LAMA therapy reduces severe asthma exacerbations
By Michael Woodhead
20 May 2021